Imatinib (GIST advanced/metastatic 1L; KIT/PDGFRA imatinib-sensitive)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-IMATINIB |
|---|
| ID | REG-IMATINIB-GIST-1L |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-IRIS-OBRIEN-2003 SRC-NCCN-GIST-2025 |
Notes
Standard 1L for advanced / metastatic GIST with imatinib-sensitive genotype (KIT exon 11 ~50%; KIT exon 9 ~10% — escalate to 800 mg; PDGFRA non-D842V exon 18; PDGFRA exon 12/14). NOT effective in PDGFRA D842V (use avapritinib 1L) or in SDH-deficient KIT/PDGFRA-WT GIST. B2222 / Demetri NEJM 2002 ORR ~67%; long-term PFS ~24 mo exon 11 vs ~12 mo exon 9. Genotype testing prior to 1L is mandatory per NCCN.
Used By
Algorithms
ALGO-GIST-1L- ALGO-GIST-1L
Indication
IND-GIST-1L-IMATINIB- IND-GIST-1L-IMATINIB